Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs.
Antiviral drugs
Coxsackievirus B
Enterovirus
Persistent infection
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
13
10
2019
revised:
06
03
2020
accepted:
23
03
2020
pubmed:
26
5
2020
medline:
2
7
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Persistent enterovirus infections create a difficult therapeutic challenge in immunocompromised patients and may also contribute to the development of chronic diseases including type 1 diabetes, cardiomyopathies, post-polio syndrome and chronic fatigue syndrome. To study the ability of antiviral drugs to eradicate such infection in vitro to evalaute their potential in the treatments of these patients. We set out to evaluate several licensed or clinically tested drugs which have shown some anti-enterovirus activity in previous studies for their ability to cure persistent infection established by two different coxsackievirus B1 strains in a pancreatic cell line (PANC-1 cells). Among all tested drugs Enviroxime, Fluoxetine, concentrated human IgG product (Hizentra) and Pleconaril were able to eradicate persistent Coxsackievirus B1 infection. The effect Enviroxime, Hizentra and Pleconaril varied between the two virus strains. The identified drugs are feasible candidates for clinical trials among patients with persistent coxsackievirus B infections or chronic enterovirus-associated diseases.
Sections du résumé
BACKGROUND
Persistent enterovirus infections create a difficult therapeutic challenge in immunocompromised patients and may also contribute to the development of chronic diseases including type 1 diabetes, cardiomyopathies, post-polio syndrome and chronic fatigue syndrome.
OBJECTIVES
To study the ability of antiviral drugs to eradicate such infection in vitro to evalaute their potential in the treatments of these patients.
STUDY DESIGN
We set out to evaluate several licensed or clinically tested drugs which have shown some anti-enterovirus activity in previous studies for their ability to cure persistent infection established by two different coxsackievirus B1 strains in a pancreatic cell line (PANC-1 cells).
RESULTS
Among all tested drugs Enviroxime, Fluoxetine, concentrated human IgG product (Hizentra) and Pleconaril were able to eradicate persistent Coxsackievirus B1 infection. The effect Enviroxime, Hizentra and Pleconaril varied between the two virus strains.
CONCLUSIONS
The identified drugs are feasible candidates for clinical trials among patients with persistent coxsackievirus B infections or chronic enterovirus-associated diseases.
Identifiants
pubmed: 32450550
pii: S1386-6532(20)30076-7
doi: 10.1016/j.jcv.2020.104334
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104334Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest I declare no conflict of interest and I approved the final manuscript.